{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:52:40Z","timestamp":1791474760707,"version":"4.3.4"},"reference-count":44,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: Dalbavancin is a long-acting lipoglycopeptide, approved for treatment of skin and skin structure infections. Its PK\/PD profile and safety allow for short hospital stays even in the case of difficult-to-treat infections requiring long courses of therapy, e.g., osteomyelitis, cardiovascular, and prosthetic infections. Objectives: We aimed to evaluate the safety and efficacy of dalbavancin in real life settings for both in-label and off-label indications. Methods: retrospective evaluation of all consecutive patients treated with dalbavancin at our site between May 2017 and September 2021. Results: A total of 100 patients treated with dalbavancin and followed up for 6 months after treatment (58% male; median age 63.5 years, median Charlson Comorbidity Index CCI = 2.7, 28% inpatients) were included with the following indications: acute bacterial skin and skin structure infections (22%), bone and prosthetic infections (57%), and cardiovascular infections (19%). Infections were caused by MSSA (30%), MRSA (5%), MR-CoNS (20%), and Streptococcus spp. (8%). In 32 cases, no isolate was obtained. The average number of infusions was 5 (s.d. = 3). Neither ensuing alteration of renal function nor neutropenia or thrombocytopenia were observed during treatment and follow-up. Two self-limiting skin rashes occurred. The overall clinical success rate was 84%\u201491% for registered and 82% for unregistered indications. The prescription of higher loading doses was the only predictor independently associated with better outcomes in multivariate models (OR: 5.2, 95%CI: 1.5\u201317.9, p &lt; 0.01). Conclusions: Dalbavancin proved to be effective for skin and skin structure infections, as well as for difficult-to-treat infections in highly comorbid patients. Regarding tolerability, our results support the use of dalbavancin for long-lasting treatments of deep-seated infections.<\/jats:p>","DOI":"10.3390\/antibiotics13111063","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T03:53:14Z","timestamp":1731383594000},"page":"1063","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Safety and Efficacy of Dalbavancin in Real Life: Retrospective Analysis of a Large Monocentric Case Series of Patients Treated for Skin\/Soft Tissue and Other Difficult-to-Treat Infections"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3483-8170","authenticated-orcid":false,"given":"Giustino","family":"Parruti","sequence":"first","affiliation":[{"name":"Infectious Disease Unit, Santo Spirito General Hospital, 65124 Pescara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4850-5182","authenticated-orcid":false,"given":"Ennio","family":"Polilli","sequence":"additional","affiliation":[{"name":"Clinical Pathology, Santo Spirito General Hospital, 65124 Pescara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2850-2848","authenticated-orcid":false,"given":"Simona","family":"Coladonato","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, Santo Spirito General Hospital, 65124 Pescara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Rapacchiale","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, Santo Spirito General Hospital, 65124 Pescara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Trave","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, Santo Spirito General Hospital, 65124 Pescara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Mazzotta","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, Santo Spirito General Hospital, 65124 Pescara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Bondanese","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, Santo Spirito General Hospital, 65124 Pescara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Masi","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, Santo Spirito General Hospital, 65124 Pescara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Recinelli","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, Santo Spirito General Hospital, 65124 Pescara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Corridoni","sequence":"additional","affiliation":[{"name":"Pharmacy Unit, Santo Spirito General Hospital, 65124 Pescara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Costantini","sequence":"additional","affiliation":[{"name":"Pharmacy Unit, Santo Spirito General Hospital, 65124 Pescara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Ianniruberto","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, Santo Spirito General Hospital, 65124 Pescara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Cacciatore","sequence":"additional","affiliation":[{"name":"Internal Medicine Day Hospital, Santo Spirito General Hospital, 65124 Pescara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Carinci","sequence":"additional","affiliation":[{"name":"Department of Statistical Sciences, University of Bologna, 40126 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"a026989","DOI":"10.1101\/cshperspect.a026989","article-title":"Approved Glycopeptide Antibacterial Drugs: Mechanism of Action and Resistance","volume":"6","author":"Zeng","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40121-015-0077-7","article-title":"Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections","volume":"4","author":"Smith","year":"2015","journal-title":"Infect. Dis. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2165\/00003495-200868050-00006","article-title":"Dalbavancin","volume":"68","author":"Anderson","year":"2008","journal-title":"Drugs"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/cid\/civ982","article-title":"A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection","volume":"62","author":"Dunne","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e02260-20","DOI":"10.1128\/AAC.02260-20","article-title":"Population Pharmacokinetics of Dalbavancin and Dosing Consideration for Optimal Treatment of Adult Patients with Staphylococcal Osteoarticular Infections","volume":"65","author":"Cojutti","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1080\/14787210.2021.1894130","article-title":"The Role of Dalbavancin for Gram Positive Infections in the COVID-19 Era: State of the Art and Future Perspectives","volume":"19","author":"Andreoni","year":"2021","journal-title":"Expert. Rev. Anti Infect. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.2147\/DDDT.S313756","article-title":"Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs","volume":"15","author":"Gatti","year":"2021","journal-title":"Drug Des. Devel Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jiph.2016.08.007","article-title":"Antibiotic Resistance","volume":"10","author":"Frieri","year":"2017","journal-title":"J. Infect. Public. Health"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1302\/2058-5241.1.000017","article-title":"Chronic Osteomyelitis: What the Surgeon Needs to Know","volume":"1","author":"Panteli","year":"2016","journal-title":"EFORT Open Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1128\/MMBR.00013-14","article-title":"Biofilm-Related Infections: Bridging the Gap between Clinical Management and Fundamental Aspects of Recalcitrance toward Antibiotics","volume":"78","author":"Lebeaux","year":"2014","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s15010-023-02152-2","article-title":"Experience with Dalbavancin Use in Various Gram-Positive Infections within Aberdeen Royal Infirmary OPAT Service","volume":"52","author":"McSorley","year":"2024","journal-title":"Infection"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1093\/cid\/civ482","article-title":"2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults","volume":"61","author":"Berbari","year":"2015","journal-title":"Clin Infect Dis"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e02280-18","DOI":"10.1128\/AAC.02280-18","article-title":"Safety and Efficacy of Prolonged Use of Dalbavancin in Bone and Joint Infections","volume":"63","author":"Morata","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1080\/14787210.2020.1798227","article-title":"Efficacy and Safety of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) and Other Infections in a Real-Life Setting: Data from an Italian Observational Multicentric Study (DALBITA Study)","volume":"18","author":"Bai","year":"2020","journal-title":"Expert. Rev. Anti Infect. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"ofy331","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety","volume":"6","author":"Rappo","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diagmicrobio.2018.10.007","article-title":"Dalbavancin for the Management of Gram-Positive Osteomyelitis: Effectiveness and Potential Utility","volume":"93","author":"Almangour","year":"2019","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s15010-020-01526-0","article-title":"Dalbavancin as Long-Term Suppressive Therapy for Patients with Gram-Positive Bacteremia Due to an Intravascular Source-a Series of Four Cases","volume":"49","author":"Hitzenbichler","year":"2021","journal-title":"Infection"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"ofab486","DOI":"10.1093\/ofid\/ofab486","article-title":"Multiple-Dose Dalbavancin Regimens as the Predominant Treatment of Deep-Seated or Endovascular Infections: A Scoping Review","volume":"8","author":"Cooper","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/cid\/ciy279","article-title":"Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna","volume":"67","author":"Tobudic","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","article-title":"Dalbavancin in the Treatment of Different Gram-Positive Infections: A Real-Life Experience","volume":"51","author":"Bouza","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/ejhpharm-2018-001711","article-title":"Dalbavancin Is a Novel Antimicrobial against Gram-Positive Pathogens: Clinical Experience beyond Labelled Indications","volume":"27","year":"2020","journal-title":"Eur. J. Hosp. Pharm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cis803","article-title":"Infectious Diseases Society of America Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guidelines by the Infectious Diseases Society of America","volume":"56","author":"Osmon","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.diagmicrobio.2016.05.009","article-title":"In Vitro Activity of Dalbavancin against Biofilms of Staphylococci Isolated from Prosthetic Joint Infections","volume":"85","author":"Patel","year":"2016","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0300-2896(11)70065-5","article-title":"[Mediastinitis]","volume":"47","year":"2011","journal-title":"Arch. Bronconeumol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"ofaa293","DOI":"10.1093\/ofid\/ofaa293","article-title":"Use of a Standardized Dalbavancin Approach to Facilitate Earlier Hospital Discharge for Vulnerable Patients Receiving Prolonged Inpatient Antibiotic Therapy","volume":"7","author":"Shihadeh","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"429.e1","DOI":"10.1016\/j.cmi.2017.07.028","article-title":"Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen","volume":"24","author":"Werth","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/cid\/ciac341","article-title":"Emergence of Dalbavancin, Vancomycin, and Daptomycin Nonsusceptible Staphylococcus aureus in a Patient Treated with Dalbavancin: Case Report and Isolate Characterization","volume":"29","author":"Zhang","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/23744235.2017.1296968","article-title":"Review of the Pharmacokinetics of Dalbavancin, a Recently Approved Lipoglycopeptide Antibiotic","volume":"49","author":"Dash","year":"2017","journal-title":"Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.12659\/AJCR.905930","article-title":"Multiple Weekly Dalbavancin Dosing for the Treatment of Native Vertebral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus Aureus: A Case Report","volume":"18","author":"Almangour","year":"2017","journal-title":"Am. J. Case Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01568-12","article-title":"Systematic Review and Meta-Analysis of Vancomycin-Induced Nephrotoxicity Associated with Dosing Schedules That Maintain Troughs between 15 and 20 Milligrams per Liter","volume":"57","author":"Paterson","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1177\/0091270005280378","article-title":"Population Pharmacokinetic Analysis of Dalbavancin, a Novel Lipoglycopeptide","volume":"45","author":"Buckwalter","year":"2005","journal-title":"J. Clin. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.diagmicrobio.2017.09.015","article-title":"Dalbavancin Is Active in Vitro against Biofilms Formed by Dalbavancin-Susceptible Enterococci","volume":"90","author":"Neudorfer","year":"2018","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-Duration Dosing and Distribution of Dalbavancin into Bone and Articular Tissue","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s40121-021-00402-0","article-title":"Safety of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Nephrotoxicity Rates Compared with Vancomycin: A Post Hoc Analysis of Three Clinical Trials","volume":"10","author":"Gonzalez","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1097\/TA.0b013e3182542fab","article-title":"Are the Frail Destined to Fail? Frailty Index as Predictor of Surgical Morbidity and Mortality in the Elderly","volume":"72","author":"Farhat","year":"2012","journal-title":"J. Trauma. Acute Care Surg."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.cger.2018.08.007","article-title":"Orthopedic Surgery and the Geriatric Patient","volume":"35","author":"Greenstein","year":"2019","journal-title":"Clin. Geriatr. Med."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Cobo, J., and Escudero-Sanchez, R. (2021). Suppressive Antibiotic Treatment in Prosthetic Joint Infections: A Perspective. Antibiotics, 10.","DOI":"10.3390\/antibiotics10060743"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Lin, H.-S., Watts, J.N., Peel, N.M., and Hubbard, R.E. (2016). Frailty and Post-Operative Outcomes in Older Surgical Patients: A Systematic Review. BMC Geriatr., 16.","DOI":"10.1186\/s12877-016-0329-8"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s15010-017-1077-1","article-title":"Suppressive Antibiotic Therapy with Oral Tetracyclines for Prosthetic Joint Infections: A Retrospective Study of 78 Patients","volume":"46","author":"Pradier","year":"2018","journal-title":"Infection"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/BF01641071","article-title":"The role of antibodies against alpha-toxin and teichoic acid in the diagnosis of staphylococcal infections","volume":"11","author":"Julander","year":"1983","journal-title":"Infection"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1186\/s12913-022-08421-4","article-title":"Reliability of predictive models to support early decision making in the emergency department for patients with confirmed diagnosis of COVID-19: The Pescara Covid Hospital score","volume":"22","author":"Polilli","year":"2022","journal-title":"BMC Health Serv. Res."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Kleinbaum, D.G., and Klein, M. (2010). Introduction to Logistic Regression. Logistic Regression: A Self-Learning Text, Springer.","DOI":"10.1007\/978-1-4419-1742-3"},{"key":"ref_44","unstructured":"R Core Team (2024, October 01). European Environment Agency. Available online: https:\/\/www.eea.europa.eu\/mobile\/data-and-maps\/indicators\/oxygen-consuming-substances-in-rivers\/r-development-core-team-2006."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/11\/1063\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:29:00Z","timestamp":1760113740000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/11\/1063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":44,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["antibiotics13111063"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics13111063","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,8]]}}}